<?xml version="1.0" encoding="UTF-8"?>
<ref id="B10-antibodies-09-00020">
 <label>10.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Rudenko</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Van Den Bosch</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Kiseleva</surname>
    <given-names>I.</given-names>
   </name>
   <name>
    <surname>Mironov</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Naikhin</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Larionova</surname>
    <given-names>N.</given-names>
   </name>
   <name>
    <surname>Bushmenkov</surname>
    <given-names>D.</given-names>
   </name>
  </person-group>
  <article-title>Live attenuated pandemic influenza vaccine: Clinical studies on A/17/California/ 2009/38 (H1N1) and licensing of the Russian-developed technology to WHO for pandemic influenza preparedness in developing countries</article-title>
  <source>Vaccine</source>
  <year>2011</year>
  <volume>29</volume>
  <fpage>A40</fpage>
  <lpage>A44</lpage>
  <pub-id pub-id-type="doi">10.1016/j.vaccine.2011.04.122</pub-id>
  <pub-id pub-id-type="pmid">21684428</pub-id>
 </element-citation>
</ref>
